Friday November 22, 2019

Dublin drug company’s value set to top €280 million in wake of US acquisition

Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion

By Ian Guider

Markets Editor

@ianguider
1st September, 2019

Chief operating officer Rory Nealon

Amryt, the Dublin-based orphan and rare disease drug firm, will have a market value of more than $300 million (€280 million) after its takeover of the US firm Aegerion.

Amryt is raising $60 million from investors in a share sale and last week raised $8 million in a placing as it looks to complete the deal with Aegerion, which is emerging from bankruptcy protection in the US. The company is also seeking a listing on the...

Subscribe from just €1 per month!

or Log in to continue reading

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Related Stories

It’s been a turbulent year for the advertising market, but it’s here in the fourth quarter that the real profits are made

Willie O'Reilly | 5 days ago

Marion McKeone profiles the billionaire, media mogul, philanthropist and perennial presidential contender

Marion McKeone | 5 days ago

Mortgage gouging by banks does not serve society well

Matt Cooper | 5 days ago